Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
36.24
+0.65 (1.83%)
At close: Jun 6, 2025, 4:00 PM
37.00
+0.76 (2.10%)
After-hours: Jun 6, 2025, 7:10 PM EDT

Company Description

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs).

Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics.

The company’s pipeline has three programs in registrational clinical trials, such as Delpacibart etedesiran, which is in Phase 3 development stage for the treatment of people with myotonic dystrophy type 1; Delpacibart braxlosiran that is in Phase 1/2 development stage for treating facioscapulohumeral muscular dystrophy; and Delpacibart zotadirsen, which is in the Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular dystrophy.

The company is also developing precision cardiology candidates targeting rare genetic cardiomyopathies, including AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome.

Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Avidity Biosciences, Inc.
Avidity Biosciences logo
Country United States
Founded 2012
IPO Date Jun 12, 2020
Industry Biotechnology
Sector Healthcare
Employees 391
CEO Sarah Boyce

Contact Details

Address:
10578 Science Center Drive, Suite 125
San Diego, California 92121
United States
Phone 858 401 7900
Website aviditybiosciences.com

Stock Details

Ticker Symbol RNA
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $18.00
CIK Code 0001574111
CUSIP Number 05370A108
ISIN Number US05370A1088
SIC Code 2834

Key Executives

Name Position
Sarah Boyce President, Chief Executive Officer and Director
Dr. Troy Edward Wilson J.D., Ph.D. Co-Founder and Independent Chairman
Michael F. MacLean CPA Chief Financial Officer
Dr. W. Michael F. Flanagan Ph.D. Chief Scientific Officer
John B. Moriarty Jr., ESQ., J.D. Chief Legal Officer and Corporate Secretary
Teresa McCarthy Chief Human Resources Officer
Prof. Mark E. Davis Ph.D. Scientific Founder, Member of Scientific Advisory Board and Member of Board of Managers
Dr. Frank P. McCormick Ph.D. Scientific Founder and Member of Scientific Advisory Board
Charles Calderaro III Chief Technical Officer
Eric B. Mosbrooker Chief Commercial Officer

Latest SEC Filings

Date Type Title
Feb 16, 2016 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 1, 2016 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
May 8, 2015 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Apr 30, 2015 20-F Annual and transition report of foreign private issuers
Mar 23, 2015 15-12B Securities registration termination
Feb 17, 2015 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 12, 2015 6-K Report of foreign issuer
Feb 12, 2015 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 11, 2015 25 Filing
Feb 10, 2015 6-K Report of foreign issuer